Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets

轻链淀粉样变性中T细胞亚群的免疫检查点表达模式:VISTA、PD-1和TIGIT作为潜在的治疗靶点

阅读:1

Abstract

Amyloid light chain (AL) amyloidosis is a rare plasma cell dyscrasia with dismal prognosis. This study aims to investigate the T-cell immune checkpoint expression patterns in systemic AL amyloidosis and its relationship with clinicobiological traits. We examined the frequencies of V-domain immunoglobulin suppressor of T cell activation(+) (VISTA(+)), programmed cell death 1(+) (PD-1(+)), T cell immunoglobulin and mucin-domain-containing-3(+) (Tim-3(+)), T cell immunoreceptor with Ig and ITIM domains(+) (TIGIT(+)) T cells in peripheral blood (PB) and bone marrow (BM) from 19 patients with newly diagnosed AL amyloidosis. Patients with AL amyloidosis had significantly higher percentages of VISTA(+) and PD-1(+) T cells in PB than healthy individuals (HIs), with no statistical differences in BM. The percentages of some double-positive T cells in PB were also considerably higher in AL amyloidosis than those in HIs. Additionally, the patients with renal involvement had more PD-1(+) and TIGIT(+) T cells than the patients without, and PD-1(+)CD3(+)%, PD-1(+)CD4(+)%, PD-1(+)Treg% were positively correlated with 24-hour proteinuria levels. Furthermore, the AL amyloidosis patients had higher counts of PD-1(+) Treg in PB than multiple myeloma (MM) patients, while the MM patients had higher counts of TIGIT(+) T cells than AL amyloidosis patients. Collectively, this is the first report of elevated proportions of VISTA(+) and PD-1(+) T cells in PB of AL amyloidosis patients, indicating an immunosuppressive milieu, and the increased PD-1(+) and TIGIT(+) T cells were associated with renal damage. VISTA, PD-1, and TIGIT may be potential targets for reversing T-cell exhaustion in AL amyloidosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。